Key Takeaways
- Sanctions and a collapsing economy have effectively cut Iran off from essential medicines and the raw materials needed to produce them, triggering huge shortages.
- The price of some critical imported drugs has shot up over 300% since 2020, putting them completely out of reach for most of the population.
- Patients with chronic and rare conditions like cancer, multiple sclerosis, and hemophilia are hit hardest by the lack of specialized treatments and their skyrocketing cost.
- Iran’s own pharmaceutical industry is trying to pick up the slack, but it can’t get the quality ingredients or technology it needs because of the same international restrictions.
- The crisis is forcing people to use black markets for medicine, which creates a whole new set of problems with counterfeit drugs and unreliable supply.
The combination of international sanctions and Iran’s own economic problems has put the country’s healthcare system in a stranglehold, especially when it comes to getting medicine. These pressures have created a very real crisis, leaving a huge number of people unable to find treatments they need to stay alive. The result is a population whose health and well-being are being directly undermined.
Sanctions’ Chilling Effect on Pharmaceutical Imports
The main reason for the medicine shortages in Iran is the long-term effect of international sanctions. Officially, humanitarian goods like medicine are exempt, but in practice, that means very little. The reality is that banks and global companies are terrified of doing business with Iran, worried they’ll get hit with secondary sanctions or take a major reputational hit. This fear completely blocks the pathways for legitimate trade, even for medical supplies.
A 2024 Reuters report noted that major European drug distributors have been pulling back or stopping direct shipments to Iran altogether, complaining about the nightmare of processing payments and working through compliance rules. The direct result is fewer specialized drugs for everything from specific cancers to advanced autoimmune diseases. This also severely restricts imports of active pharmaceutical ingredients (APIs) and manufacturing equipment, crippling Iran’s ability to make its own drugs. We’re talking about complex biologics and specialized treatments that have almost no alternative suppliers, not simple things like aspirin.
The red tape alone is unbelievable. Getting letters of credit, finding a bank willing to handle the money, and then arranging transport with a shrinking list of carriers adds months of delays and drives up costs. A pharma importer in Tehran told the Associated Press in late 2025 (anonymously, of course) that it took him six months just to get a shipment of insulin pens, a process that used to take less than two. For patients who need their medication on a strict schedule, delays like that can be a death sentence.
Escalating Medicine Costs and Affordability Crisis
Even when a drug is available, its cost has become a massive wall for most Iranian families. The Iranian rial has been devalued so much against other currencies that imported medicines are now astronomically expensive. On top of that, the short supply means prices get driven up even more on the open market.
According to data from Iran’s Ministry of Health and Medical Education, the average price tag on imported specialty drugs has jumped by 250% to 300% since 2020. A single course of treatment for a certain type of multiple sclerosis, which was already expensive, can now cost more than what an average family earns in an entire year. This forces an impossible choice on people: pay for medicine or pay for food and rent.
The situation is worst for anyone needing long-term treatment. For instance, hemophilia patients need constant access to expensive clotting factor concentrates. When they can’t get them or afford them, the risk of severe internal bleeding and permanent joint damage goes through the roof. The government has subsidy programs, but they can’t possibly keep up with the inflation and the sheer number of people in need, leaving a huge gap between what’s available and what’s actually affordable. The awful truth is that a drug might as well not exist if you can’t pay for it.
Disproportionate Impact on Vulnerable Patient Groups
This crisis doesn’t hit everyone the same. The people suffering the most are patients with rare diseases, certain types of cancer, and chronic conditions like thalassemia, multiple sclerosis, and kidney failure. Their treatments often depend on highly specific medications made by only a few companies in the world, making them extremely vulnerable to these supply chain breakdowns.
For cancer patients, any delay in getting chemotherapy drugs can wreck the treatment’s effectiveness and lower their chances of survival. Oncology wards in major hospitals, like Tehran’s Imam Khomeini Hospital, have been reporting constant shortages of chemo agents and supportive care drugs since early 2025. Doctors are forced to make terrible choices, like rationing what little they have or switching to older, less effective drugs. You can only imagine the mental toll on patients and families who are fighting a deadly disease while also having to hunt for the medicine to treat it.
It’s a similar story for children with genetic disorders who need specific enzyme replacement therapies. These treatments are often proprietary, made by one or two companies globally. Being unable to import these drugs doesn’t just hurt their health, it permanently damages their development. This is a fundamental denial of basic medical care that’s readily available in other parts of the world.
Challenges to Domestic Pharmaceutical Production
Iran has tried to fight back against the external pressure by building up its own domestic drug industry and aiming for self-sufficiency. There have been some successes, but the effort is hobbled by the exact same sanctions that block finished drug imports. Iran’s local industry is completely dependent on imported raw materials, APIs, and specialized machinery.
A mid-2025 report from the Iranian Pharmaceutical Association stated that over 70% of the raw materials for drugs made in Iran are imported. Getting these materials involves the same banking and shipping nightmares as finished products, which means supply is spotty and production costs are high. And with limited access to modern manufacturing tech and quality control gear, there are real questions about the effectiveness and safety of some locally made drugs. The goal of a strong domestic industry is a good one, but it’s a fantasy without access to the global supply chain.
Intellectual property and R&D are also a huge problem. To develop new, complex drugs, you need massive investment, collaboration with international scientists, and the ability to license patents. Sanctions have almost totally isolated Iranian pharma researchers from the rest of the world which slows down innovation to a crawl. The result is a dependency on generics or much older drugs that aren’t always the best option.
The Rise of Parallel Markets and Associated Risks
With official channels either empty or too expensive, it was inevitable that a black market for medicine would explode. These informal networks can sometimes be the only option for desperate patients, but they are incredibly risky. There’s no way to know if the drugs are real or safe, and a lot of them are counterfeit or low-quality.
A late 2024 study from the Medical University of Tehran looked at heart disease and diabetes medications sold on the black market and found that about 15% of the samples were either expired, stored improperly, or had the wrong dosage. These fake drugs don’t just fail to work, they can cause serious harm. People who are already sick and scared are forced to take a huge gamble with their health because they have no other choice.
And to make it all worse, the prices on these parallel markets are often even more inflated than in pharmacies, as sellers exploit people’s desperation. It’s a downward spiral: financial hardship pushes people to take risks, which in turn destroys their health and finances even further. This is what happens when the system completely fails its people.
The healthcare and medicine situation in Iran is a humanitarian disaster. The combination of sanctions, economic failure, and logistical blockades has created an environment where getting life-saving medicine is a daily struggle. The only way forward is to find a way to separate humanitarian needs from political fights and make sure people’s basic right to health is protected.
How exactly do sanctions block medicine from getting into Iran?
Even though medicine is technically exempt from sanctions, the rules are so complex that international banks and shipping companies refuse to do business with Iran. They’re afraid of being hit with massive fines or other penalties, so they just say no. This makes it nearly impossible to pay for and ship medicine, raw ingredients, and manufacturing equipment into the country.
Who’s getting hit the hardest by these shortages?
The shortages disproportionately hurt patients with chronic and rare conditions. People with cancer, multiple sclerosis, thalassemia, and hemophilia often need very specific, imported drugs that have no local equivalent. When the supply chain for these drugs breaks down, these patients are left with few or no options.
Have drug prices really gone up that much in Iran?
Yes, prices for imported specialty drugs have gone up by an estimated 250% to 300% since 2020, based on government data. This is because Iran’s currency has lost so much value, and the limited supply of medicine has allowed prices to skyrocket.
Why can’t Iran just make all its own medicine?
Iran’s domestic drug industry is trying, but it depends heavily on imported raw materials and active pharmaceutical ingredients (APIs) to make medicine. Because of sanctions, it’s just as hard to import these ingredients as it is to import finished drugs. They’re also cut off from a lot of modern manufacturing technology and international research which limits what they can produce.
What are the dangers of buying medicine on the black market?
The black market is filled with fake, expired, or improperly stored drugs that can be useless or even dangerous. A recent study found a significant percentage of these drugs were bad. On top of the health risks, sellers on the black market often charge even more than official pharmacies, taking advantage of people’s desperation.